Advances in the study of inhibitors of kinases and nuclear factors for treating allergic asthma.
- Author:
Ren-Ping LIU
1
;
Ai-Min MENG
;
Qi HOU
Author Information
1. Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Asthma;
drug therapy;
enzymology;
Humans;
Mitogen-Activated Protein Kinases;
antagonists & inhibitors;
Phosphatidylinositol 3-Kinase;
antagonists & inhibitors;
Protein Kinase Inhibitors;
therapeutic use;
Protein-Tyrosine Kinases;
antagonists & inhibitors;
metabolism;
Signal Transduction;
Transcription Factors;
antagonists & inhibitors
- From:
Acta Pharmaceutica Sinica
2012;47(6):689-695
- CountryChina
- Language:Chinese
-
Abstract:
Currently, about 300 million people worldwide are affected by asthma. Most of these sufferers inhale immunosuppressants (ie corticosteroids) and beta-adrenergic receptor agonists for their asthma treatment. However, about 5%-10% of patients of asthma have poor response to such treatment. Investigation of kinase signaling pathway and nuclear transcription factor as a target molecule in the treatment of allergic asthma has been the concern of scholars home and abroad. This paper reviewed inhibitors of kinase signaling pathway and nuclear transcription factors for the treatment of asthma.
